{"protocolSection":{"identificationModule":{"nctId":"NCT00568997","orgStudyIdInfo":{"id":"CASM981C2311"},"organization":{"fullName":"Bausch Health Americas, Inc.","class":"INDUSTRY"},"briefTitle":"10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus","officialTitle":"A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two Years to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Elidel Cream 1% (Pimecrolimus)","acronym":"PEER"},"statusModule":{"statusVerifiedDate":"2024-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-06-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2007-12-05","studyFirstSubmitQcDate":"2007-12-05","studyFirstPostDateStruct":{"date":"2007-12-06","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-02-22","lastUpdatePostDateStruct":{"date":"2024-02-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bausch Health Americas, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Clinical Research Computing Unit (University of Pennsylvania)","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.","detailedDescription":"Registry study to examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream."},"conditionsModule":{"conditions":["Atopic Dermatitis"],"keywords":["Atopic dermatitis eczema pediatric pimecrolimus malignancy"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"CASE_CONTROL","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":8000,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"1","description":"Single-group Open Label Registry of patients exposed to Elidel/Pimecrolimus","interventionNames":["Drug: Pimecrolimus"]}],"interventions":[{"type":"DRUG","name":"Pimecrolimus","description":"Pimecrolimus 1% cream","armGroupLabels":["1"],"otherNames":["Elidel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The incidence rate of systemic malignancies in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream","timeFrame":"10 years of observation with 6-month reporting intervals"}],"secondaryOutcomes":[{"measure":"The incidence rate of lymphoma in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream","timeFrame":"10 years of observation with 6-month reporting intervals"},{"measure":"The incidence rate of thyroid cancer in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream","timeFrame":"10 years of observation with 6-month reporting intervals"},{"measure":"The incidence rate of cutaneous malignancy in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream","timeFrame":"10 years of observation with 6-month reporting intervals"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* males and females\n* greater than or equal to 2 years and less than or equal to 17 years at enrollment\n* diagnosis of atopic dermatitis (confirmed by treating physician)\n* applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks\n\nExclusion Criteria:\n\n* past or present history of systemic malignancy, skin malignancy, or lymphoproliferative disease\n* past or present use of oral immunosuppressive therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"17 Years","stdAges":["CHILD"],"studyPopulation":"Children (ages 2-17 years)","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Sandra Narain","role":"CONTACT","phone":"908-242-8287","email":"sandra.narain@bauschhealth.com"}],"overallOfficials":[{"name":"Anya Loncaric","affiliation":"Bausch Health","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Registry","status":"RECRUITING","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","contacts":[{"name":"NA NA","role":"CONTACT"}],"geoPoint":{"lat":39.95233,"lon":-75.16379}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-08-28"},"conditionBrowseModule":{"meshes":[{"id":"D000003876","term":"Dermatitis, Atopic"},{"id":"D000003872","term":"Dermatitis"},{"id":"D000004485","term":"Eczema"}],"ancestors":[{"id":"D000012871","term":"Skin Diseases"},{"id":"D000012873","term":"Skin Diseases, Genetic"},{"id":"D000030342","term":"Genetic Diseases, Inborn"},{"id":"D000017443","term":"Skin Diseases, Eczematous"},{"id":"D000006969","term":"Hypersensitivity, Immediate"},{"id":"D000006967","term":"Hypersensitivity"},{"id":"D000007154","term":"Immune System Diseases"}],"browseLeaves":[{"id":"M7067","name":"Dermatitis","asFound":"Dermatitis","relevance":"HIGH"},{"id":"M7655","name":"Eczema","asFound":"Atopic Dermatitis","relevance":"HIGH"},{"id":"M7071","name":"Dermatitis, Atopic","asFound":"Atopic Dermatitis","relevance":"HIGH"},{"id":"M15674","name":"Skin Diseases","relevance":"LOW"},{"id":"M15676","name":"Skin Diseases, Genetic","relevance":"LOW"},{"id":"M23686","name":"Genetic Diseases, Inborn","relevance":"LOW"},{"id":"M19712","name":"Skin Diseases, Eczematous","relevance":"LOW"},{"id":"M10018","name":"Hypersensitivity","relevance":"LOW"},{"id":"M10020","name":"Hypersensitivity, Immediate","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC16","name":"Diseases and Abnormalities at or Before Birth"},{"abbrev":"BC20","name":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000117268","term":"Pimecrolimus"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000003879","term":"Dermatologic Agents"},{"id":"D000007166","term":"Immunosuppressive Agents"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000065095","term":"Calcineurin Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M242993","name":"Pimecrolimus","asFound":"Study population","relevance":"HIGH"},{"id":"M4218","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M4217","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M4032","name":"Analgesics","relevance":"LOW"},{"id":"M20786","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20604","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M7074","name":"Dermatologic Agents","relevance":"LOW"},{"id":"M10212","name":"Immunosuppressive Agents","relevance":"LOW"},{"id":"M10201","name":"Immunologic Factors","relevance":"LOW"},{"id":"M30452","name":"Calcineurin Inhibitors","relevance":"LOW"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"Derm","name":"Dermatologic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}